{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:07:00Z","timestamp":1789056420800,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Jeddah","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omta.2026.201763","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T15:51:47Z","timestamp":1779465107000},"page":"201763","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epitope mapping of humoral immunogenicity of orvacabtagene autoleucel shows an IgM response with minimal impact on CAR T cellular kinetics"],"prefix":"10.1016","volume":"34","author":[{"given":"Xianghong","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanshan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pazos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochem","family":"Gokemeijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ogasawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oda","family":"Stoevesandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Mora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7019-729X","authenticated-orcid":false,"given":"Vibha","family":"Jawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201763_bib1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.omta.2026.201763_bib2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201763_bib3","first-page":"1656","article-title":"Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus","volume":"25","author":"Mackensen","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201763_bib4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41584-024-01139-z","article-title":"Advancements and challenges in CAR T cell therapy in autoimmune diseases","volume":"20","author":"Schett","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.omta.2026.201763_bib5","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","article-title":"Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): update of the phase 1\/2 EVOLVE study (NCT03430011)","volume":"38","author":"Mailankody","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.omta.2026.201763_bib6","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1158\/1078-0432.CCR-24-2753","article-title":"Population pharmacokinetics of orvacabtagene autoleucel, an autologous BCMA-directed chimeric antigen receptor T-cell product, in patients with relapsed\/refractory multiple myeloma","volume":"31","author":"Hu","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.omta.2026.201763_bib7","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.3390\/cancers13112639","article-title":"CART-cell therapy: recent advances and new evidence in multiple myeloma","volume":"13","author":"Martino","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.omta.2026.201763_bib8","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt.15.77","article-title":"Targeting B-cell maturation antigen in multiple myeloma","volume":"7","author":"Tai","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.omta.2026.201763_bib9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","article-title":"BCMA-targeted immunotherapy for multiple myeloma","volume":"13","author":"Yu","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.omta.2026.201763_bib10","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/10428194.2023.2284088","article-title":"BCMA-directed therapy, new treatments in the myeloma toolbox, and how to use them","volume":"65","author":"Rees","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.omta.2026.201763_bib11","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.omta.2026.201763_bib12","first-page":"26","article-title":"Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in patients with relapsed and refractory multiple myeloma: updated results from phase 1 CRB-401 study","volume":"136","author":"Lin","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201763_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","article-title":"Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.omta.2026.201763_bib14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201763_bib15","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40259-019-00354-5","article-title":"Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics","volume":"33","author":"Gorovits","year":"2019","journal-title":"BioDrugs"},{"key":"10.1016\/j.omta.2026.201763_bib16","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.omta.2026.201763_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1512494","article-title":"Clinical evidence of immunogenicity of CAR-T cell therapies and its implication in the clinical development of CAR-T drug products","volume":"16","author":"Alfar","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201763_bib18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/cpt.3111","article-title":"An IQ Consortium Perspective on Best Practices for Bioanalytical and Immunogenicity Assessment Aspects of CAR-T and TCR-T Cellular Therapies Development","volume":"115","author":"Gokemeijer","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.omta.2026.201763_bib19","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2019.1707418","article-title":"T cell epitope mapping of secukinumab and ixekizumab in healthy donors","volume":"12","author":"Spindeldreher","year":"2020","journal-title":"mAbs"},{"key":"10.1016\/j.omta.2026.201763_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.886546","article-title":"Immunogenicity of CAR-T-cell therapeutics: evidence, mechanism, and mitigation","volume":"13","author":"Khan","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201763_bib21","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.xphs.2024.05.018","article-title":"Immunogenicity risk assessment of process-related impurities in an engineered T cell receptor cellular product","volume":"113","author":"Mora","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.omta.2026.201763_bib24","first-page":"3473","article-title":"CAR T-cell therapy: is it prime time in myeloma?","volume":"3","author":"Sidana","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.omta.2026.201763_bib25","doi-asserted-by":"crossref","first-page":"5290","DOI":"10.1182\/bloodadvances.2021004603","article-title":"Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed\/refractory multiple myeloma","volume":"5","author":"Wang","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.omta.2026.201763_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-59745-450-6_1","article-title":"What is a B-cell epitope?","volume":"524","author":"Van Regenmortel","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.omta.2026.201763_bib27","series-title":"Janeway\u2019s Immunobiology","first-page":"400","article-title":"B-cell activation by antigen and helper T cells","author":"Murphy","year":"2017"},{"key":"10.1016\/j.omta.2026.201763_bib28","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nri3818","article-title":"The ins and outs of MHC class II-mediated antigen processing and presentation","volume":"15","author":"Roche","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.omta.2026.201763_bib29","first-page":"376","article-title":"Immunogenicity of CAR T cells: potential causes and consequences","volume":"8","author":"Hartmann","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.omta.2026.201763_bib30","first-page":"34","article-title":"Cell-therapy immunogenicity: current understanding and mitigation strategies","volume":"31","author":"Mougel","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201763_bib31","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1084\/jem.20031330","article-title":"BCMA is essential for the survival of long-lived bone-marrow plasma cells","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.omta.2026.201763_bib32","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.1182\/blood-2011-01-330852","article-title":"Development and characterization of APRIL antagonistic monoclonal antibodies for treatment of B-cell lymphomas","volume":"117","author":"Guadagnoli","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201763_bib33","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2005-09-3613","article-title":"Impaired class-switch recombination in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"107","author":"Kriangkum","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.omta.2026.201763_bib34","first-page":"1388","article-title":"Aberrant immunoglobulin class-switch recombination, and switch junctions in B-cell malignancies","volume":"21","author":"Lenz","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.omta.2026.201763_bib35","first-page":"487","article-title":"AAPS White Paper: consensus recommendations on anti-drug antibody assay strategy, data analysis, and interpretation","volume":"16","author":"Sailstad","year":"2014","journal-title":"AAPS J."},{"key":"10.1016\/j.omta.2026.201763_bib36","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s40262-025-01531-2","article-title":"Population cellular kinetics of idecabtagene vicleucel in patients with triple-class\u2013exposed relapsed\/refractory multiple myeloma","volume":"64","author":"Wu","year":"2025","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.omta.2026.201763_bib38","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s40262-021-01039-5","article-title":"Population cellular kinetics of lisocabtagene maraleucel, an autologous CD19-directed chimeric antigen receptor T-cell product, in patients with relapsed\/refractory large B-cell lymphoma","volume":"60","author":"Ogasawara","year":"2021","journal-title":"Clin. Pharmacokinet."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26000984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:14:08Z","timestamp":1789053248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26000984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3117387X26000984"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201763","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epitope mapping of humoral immunogenicity of orvacabtagene autoleucel shows an IgM response with minimal impact on CAR T cellular kinetics","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201763","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201763"}}